Ascendis to Repurchase Up to $400mln of Shares Under Planned Program

Ascendis Pharma A/S plans to repurchase up to $400 million of its ordinary shares under a new share repurchase program. The timing and amount of repurchases will be determined by market conditions, share price, and other factors. The program may be modified, suspended, or terminated at any time without notice. The Danish biopharmaceutical company is focused on developing new therapies using its TransCon technology platform. Ascendis is headquartered in Copenhagen, Denmark, and has facilities in Europe and the United States.